Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial

被引：0

作者：

Masatoshi Kudo

Takuji Okusaka

Kenta Motomura

Izumi Ohno

Manabu Morimoto

Satoru Seo

Yoshiyuki Wada

Shinpei Sato

Tatsuya Yamashita

Masayuki Furukawa

Takeshi Aramaki

Seijin Nadano

Kazuyoshi Ohkawa

Hirofumi Fujii

Toshihiro Kudo

Junji Furuse

Hiroki Takai

Gosuke Homma

Reigetsu Yoshikawa

Andrew X. Zhu

机构：

[1] Kindai University Faculty of Medicine,Department of Gastroenterology and Hepatology

[2] National Cancer Center Hospital,Graduate School of Medicine

[3] Aso Iizuka Hospital,Graduate School of Medicine

[4] National Cancer Center Hospital East,Graduate School of Medicine

[5] Kanagawa Cancer Center,undefined

[6] Kyoto University,undefined

[7] National Hospital Organization Kyushu Medical Center,undefined

[8] Kyoundo Hospital,undefined

[9] Sasaki Institute,undefined

[10] Kanazawa University,undefined

[11] National Hospital Organization Kyushu Cancer Center,undefined

[12] Shizuoka Cancer Center Hospital,undefined

[13] National Hospital Organization Shikoku Cancer Center,undefined

[14] Osaka International Cancer Institute,undefined

[15] Jichi Medical University,undefined

[16] Osaka University,undefined

[17] Kyorin University Faculty of Medicine,undefined

[18] Eli Lilly Japan K.K.,undefined

[19] Massachusetts General Hospital Cancer Center,undefined

[20] Harvard Medical School,undefined

来源：

Journal of Gastroenterology | 2020年 / 55卷

关键词：

Alpha-fetoprotein; Hepatocellular carcinoma; Japanese subanalysis; Ramucirumab; VEGFR2;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：627 / 639

页数：12

共 50 条

[1] Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial
Kudo, Masatoshi
Okusaka, Takuji
Motomura, Kenta
Ohno, Izumi
Morimoto, Manabu
Seo, Satoru
Wada, Yoshiyuki
Sato, Shinpei
Yamashita, Tatsuya
Furukawa, Masayuki
Aramaki, Takeshi
Nadano, Seijin
Ohkawa, Kazuyoshi
Fujii, Hirofumi
Kudo, Toshihiro
Furuse, Junji
Takai, Hiroki
Homma, Gosuke
Yoshikawa, Reigetsu
Zhu, Andrew X.
JOURNAL OF GASTROENTEROLOGY, 2020, 55 (06) : 627 - 639
[2] Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2
Kudo, Masatoshi
Galle, Peter R.
Llovet, Josep M.
Finn, Richard S.
Vogel, Arndt
Motomura, Kenta
Assenat, Eric
Merle, Philippe
Brandi, Giovanni
Daniele, Bruno
Okusaka, Takuji
Tomasek, Jiri
Borg, Christophe
Dadduzio, Vincenzo
Morimoto, Manabu
Pracht, Marc
Jen, Min-Hua
Drove Ubreva, Nora
Widau, Ryan C.
Shinozaki, Kenta
Yoshikawa, Reigetsu
Zhu, Andrew X.
LIVER INTERNATIONAL, 2020, 40 (08) : 2008 - 2020
[3] Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2
Finn, Richard S.
Yau, Thomas
Hsu, Chih-Hung
De Toni, Enrico N.
Goyal, Lipika
Galle, Peter R.
Qin, ShuKui
Rao, Sujata
Sun, Fangfang
Wang, Chunxiao
Widau, Ryan C.
Zhu, Andrew X.
ONCOLOGIST, 2022, 27 (12): : E938 - E948
[4] Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α-fetoprotein
Zhu, Andrew X.
Finn, Richard S.
Galle, Peter R.
Llovet, Josep M.
Kudo, Masatoshi
LANCET ONCOLOGY, 2019, 20 (04): : E191 - E191
[5] A study of ramucirumab (LY3009806) versus placebo in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein (REACH-2).
Zhu, Andrew X.
Galle, Peter R.
Kudo, Masatoshi
Finn, Richard S.
Qin, Shukui
Xu, Yihuan
Abada, Paolo
Llovet, Josep
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[6] Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study
Shao, Guoliang
Bai, Yuxian
Yuan, Xianglin
Chen, Xiaomin
Gu, Shanzhi
Gu, Kangsheng
Hu, Chunhong
Liang, Houjie
Guo, Yabing
Wang, Jufeng
Yen, Chia-Jui
Lee, Victor Ho-Fun
Wang, Chunxiao
Widau, Ryan C.
Zhang, Wanli
Liu, Junjun
Zhang, Qiang
Qin, Shukui
ECLINICALMEDICINE, 2022, 54
[7] Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein
Yen, Chih-Chieh
Yen, Chia-Jui
EXPERT OPINION ON DRUG SAFETY, 2022, 21 (02) : 157 - 166
[8] Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: Outcomes by liver disease aetiology from two randomised, placebo-controlled phase 3 studies (REACH-2 and REACH)
Galle, Peter
Kudo, Masatoshi
Llovet, Josep M.
Finn, Richard
Karwal, Mark
Denis, Pezet
Kim, Tae-You
Yang, Tsai-Sheng
Zagonel, Vittorina
Tomasek, Jiri
Phelip, Jean-Marc
Touchefeu, Yann
Koh, Su-Jin
Stirnimann, Guido
Wang, Chunxiao
Widau, Ryan
Hsu, Yanzhi
Abada, Paolo B.
Zhu, Andrew
JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E46 - E46
[9] Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)
Meyer, T.
Finn, R.
Kudo, M.
Kang, Y.
Yen, C.
Galle, P.
Llovet, J.
Assenat, E.
Brandi, G.
Motomura, K.
Okusaka, T.
Hubner, R.
Karwal, M.
Baron, A.
Ikeda, M.
Liang, K.
Wang, C.
Widau, R.
Schelman, W.
Zhu, A.
ANNALS OF ONCOLOGY, 2019, 30
[10] Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2)
Kudo, Masatoshi
Finn, Richard S.
Morimoto, Manabu
Rau, Kun-Ming
Ikeda, Masafumi
Yen, Chia-Jui
Galle, Peter R.
Llovet, Josep M.
Daniele, Bruno
Lim, Ho Yeong
McIlwain, David W.
Yoshikawa, Reigetsu
Nakamura, Kenichi
Liang, Kun
Wang, Chunxiao
Abada, Paolo
Widau, Ryan C.
Zhu, Andrew X.
LIVER CANCER, 2021, 10 (05) : 451 - 460

← 1 2 3 4 5 →